Host Factor Targeted Drug Discovery for SARS-CoV-2 Through an International Collaboration
New variants of SARS-CoV-2 show enhanced replication and the potential to evade therapeutic antibodies. In order to develop therapeutic approaches which act in a pan-coronavirus manner, we have mapped the human proteins (host factors) which multiple coronaviruses rely on for replication. Through a rapid drug repurposing effort we have identified zotatifin, a clinical eIF4A inhibitor as a host factor targeted therapeutic. Other examples of targeting essential host factors, including those for immune evasion will be discussed.